Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

Neurology

Volumn 90, Issue 14, 2018, Pages e1204-e1211

  Devinsky, Orrin ^a   Patel, Anup D ^a   Thiele, Elizabeth A ^a   Wong, Matthew H ^a   Appleton, Richard ^a   Harden, Cynthia L ^a   Greenwood, Sam ^a   Morrison, Gilmour ^a   Sommerville, Kenneth ^a  

^a MOUNT SINAI HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CANNABIDIOL; CLOBAZAM; N-DESMETHYLCLOBAZAM;

BLOOD; CHILD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; MULTICENTER STUDY; MYOCLONUS EPILEPSY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTICONVULSANTS; BENZODIAZEPINES; CANNABIDIOL; CHILD; CHILD, PRESCHOOL; CLOBAZAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSIES, MYOCLONIC; FOLLOW-UP STUDIES; HUMANS; TREATMENT OUTCOME;

EID: 85047303144     PISSN: None     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000005254     Document Type: Article

References (0)